OpGen, Inc. (OPGN)
- Previous Close
4.8000 - Open
5.1500 - Bid 4.8000 x 40000
- Ask 4.9800 x 43500
- Day's Range
4.7100 - 5.2500 - 52 Week Range
0.5270 - 5.3000 - Volume
7,633 - Avg. Volume
12,286 - Market Cap (intraday)
50.139M - Beta (5Y Monthly) -1.71
- PE Ratio (TTM)
-- - EPS (TTM)
-15.5300 - Earnings Date Jun 2, 2025 - Jun 6, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
OpGen, Inc., a precision medicine company, develops and commercializes molecular microbiology solutions for life threatening infectious diseases in the United States and internationally. The company's products include Unyvero application cartridges, Unyvero systems, Acuitas AMR Gene Panel test products, and SARS CoV-2 test kits. It provides laboratory services; collaboration services, including funded software arrangements; and license arrangements services. OpGen, Inc. was incorporated in 2001 and is headquartered in Rockville, Maryland.
www.opgen.comRecent News: OPGN
View MorePerformance Overview: OPGN
Trailing total returns as of 5/7/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: OPGN
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: OPGN
View MoreValuation Measures
Market Cap
50.14M
Enterprise Value
50.75M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
11.70
Price/Book (mrq)
16.79
Enterprise Value/Revenue
40.09
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-31.63%
Return on Equity (ttm)
-331.94%
Revenue (ttm)
1.27M
Net Income Avi to Common (ttm)
-9.92M
Diluted EPS (ttm)
-15.5300
Balance Sheet and Cash Flow
Total Cash (mrq)
1.63M
Total Debt/Equity (mrq)
69.01%
Levered Free Cash Flow (ttm)
-3.82M